Kristin Wynholds - Better Therapeutics Chief Officer
| BTTXDelisted Stock | USD 0.73 0.04 5.19% |
Insider
Kristin Wynholds is Chief Officer of Better Therapeutics
| Age | 52 |
| Phone | 415 887 2311 |
| Web | https://www.bettertx.com |
Better Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.9505) % which means that it has lost $0.9505 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.2164) %, meaning that it created substantial loss on money invested by shareholders. Better Therapeutics' management efficiency ratios could be used to measure how well Better Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Better Therapeutics currently holds 14.88 M in liabilities with Debt to Equity (D/E) ratio of 0.81, which is about average as compared to similar companies. Better Therapeutics has a current ratio of 5.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Better Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Better Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Better Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Better to invest in growth at high rates of return. When we think about Better Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Eric Easom | AN2 Therapeutics | 56 | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Paul MD | AN2 Therapeutics | 54 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| Crystal Mercado | Acrivon Therapeutics, Common | N/A | |
| Sanjay Chanda | AN2 Therapeutics | 59 | |
| Rasmus HolmJorgensen | Acrivon Therapeutics, Common | 52 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| Daniel Schneiderman | Pasithea Therapeutics Corp | 46 | |
| Brian MD | Rezolute | 49 | |
| Leila MD | Pmv Pharmaceuticals | 61 | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| Michael Newman | Indaptus Therapeutics | 68 | |
| Surendra Singh | Inhibikase Therapeutics | N/A | |
| TsungShann Jiang | ABVC Biopharma | 70 | |
| Steven Ruhl | Forte Biosciences | 67 | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Kristina Masson | Acrivon Therapeutics, Common | 44 | |
| Fangyong Du | Adagene | 54 | |
Management Performance
| Return On Equity | -10.22 | ||||
| Return On Asset | -0.95 |
Better Therapeutics Leadership Team
Elected by the shareholders, the Better Therapeutics' board of directors comprises two types of representatives: Better Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Better. The board's role is to monitor Better Therapeutics' management team and ensure that shareholders' interests are well served. Better Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Better Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Karbe, Interim CEO | ||
| Thiago Oliveira, Chief Officer | ||
| Angela Willis, Senior Access | ||
| Kevin Appelbaum, CoFounder Director | ||
| Jessica Meng, Chief Officer | ||
| Mark MD, Chief Officer | ||
| Mark Heinen, Head CFO | ||
| Kristin Wynholds, Chief Officer | ||
| Leslie Miller, Controller | ||
| Andres Camacho, Senior Engineering | ||
| David MBA, CoFounder Chairman | ||
| Diane GomezThinnes, Chief Officer |
Better Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Better Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.22 | ||||
| Return On Asset | -0.95 | ||||
| Current Valuation | 8.83 M | ||||
| Shares Outstanding | 54.52 M | ||||
| Shares Owned By Insiders | 53.41 % | ||||
| Shares Owned By Institutions | 2.94 % | ||||
| Number Of Shares Shorted | 2.13 M | ||||
| Price To Book | 2.29 X | ||||
| Price To Sales | 49,559 X | ||||
| Gross Profit | (674 K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Better OTC Stock
If you are still planning to invest in Better Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Better Therapeutics' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |